Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Bonjour from the City of Light!
Thrilled to have arrived in Paris, France, for the ESMO TAT Symposium 2025 – a hub of innovation and collaboration for new drugs and latest and greatest in oncology.
It’s an incredible honor to be invited to deliver the Keynote lecture at such a prestigious meeting.
Join me today as I explore the topic ‘Revolutionising Cancer Treatment: The Transformative Odyssey of Tumour-Agnostic Drug Development in Precision Medicine.’
Together, we’ll explore the groundbreaking advancements reshaping cancer therapy and the promise they hold for patients worldwide.
- When: Tuesday, March 4th, 2025
- Time: 14:00- 14:55
Looking forward to sharing insights and engaging with fellow pioneers in this exciting field.
Thanks to the organizers for the invite to talk and the forward-thinking visionary meeting.
Let’s continue to push the boundaries of what’s possible in cancer treatment!”
More posts featuring Vivek Subbiah.